Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
Authors:
Open Access
- 1 July 2014
- journal article
- review article
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. 6, 71-7
Abstract
Active surveillance (AS) is a widely recognized and utilized option by which prostate cancer patients with less aggressive tumors on diagnosis defer immediate traditional conventional therapy (surgery, radiation) and undergo close monitoring by a physician for any clinical or pathologic changes. The juxtaposition of low- to intermediate-risk elderly patients between effective and conventional treatment with associated risks and monitoring without the opportunity for relief of anxiety and other psychological problems can be significant. Minimal and safe treatment over 6 months with the hope of eliminating the existing disease is of significant interest to prostate cancer patients. Unfortunately, dietary supplements have failed to improve and have sometimes even contributed to disease progression. In addition, the use of multiple medications is not always appropriate or safe. In this case study, we administered low doses of enzalutamide (80 mg/day–120 mg/day) in an AS patient during a 6 month period. Results showed a significant reduction in tumor size, as evidenced by magnetic resonance imaging and color Doppler, as well as a an undetectable level of prostate specific antigen during, and immediately following treatment. The use of an oral second-generation androgen-receptor signaling inhibitor was shown to be of benefit to patients unwilling to pursue AS and conventional treatment. Administration of enzalutamide did not reduce testosterone levels, but helped maintain good quality of life, was more cost effective at low doses, and was previously shown to be heart healthy and efficacious during early stages of castration-resistant prostate cancer. Although we do not advocate enzalutamide as a treatment approach in these situations, we believe that a clinical trial to evaluate short-term low-dose treatment using enzalutamide is warranted.Keywords
This publication has 50 references indexed in Scilit:
- Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II studyWorld Journal of Urology, 2013
- Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancerBJU International, 2012
- Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary SupplementUrologic Clinics of North America, 2011
- Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole AloneClinical Genitourinary Cancer, 2009
- The NSABP Study of Tamoxifen and Raloxifene (STAR) trialExpert Review of Anticancer Therapy, 2009
- Vitamins E and C in the Prevention of Prostate and Total Cancer in MenJAMA, 2009
- Vitamins E and C in the Prevention of Cardiovascular Disease in MenJAMA, 2008
- Outcomes Following Active Surveillance of Men With Localized Prostate Cancer Diagnosed in the Prostate Specific Antigen EraJournal of Urology, 2008
- The Relationship Between Anxiety and Time to Treatment for Patients With Prostate Cancer on SurveillanceJournal of Urology, 2007
- Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trialBritish Journal of Urology, 1998